Small Cap Feast

11th March 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 


Delistings: 




Whats baking in the oven?

Potential Initial Public Offerings:


Reverse Takeovers:


Change of Market:


Banquet Buffet

Bidstack 0.225p £2.9m (BIDS.L)
The technology Company that empowers video game publishers to monetise and manage spaces within their virtual environments announces that it has requested a suspension of trading in the Company's ordinary shares on AIM with effect from 07.30 a.m. today. The Directors are taking this action to protect the interests of the Group's creditors.

*Coro Energy 0.185p £5.3m (CORO.L)
The South East Asian energy Company with a natural gas and clean energy portfolio announces that it has submitted an application to the Philippines Department of Energy for a second 100MW Wind Energy Service Contract (WESC). Coro has now submitted a second application for a WESC for its next wind turbine project, located in Oslob, Cebu. This second area of interest neighbours the Company's first project site and would be in respect of an additional installed capacity of circa 100MW. At midday on Friday afternoon the 8th March the Company announced the signature of a Power Purchase Agreement with Mobile World Group to cover the pilot phase of the 50MW project.

FRP Advisory 114.25p £286.7m (FRP.L)
The business advisory firm which offers a range of advisory services to companies, lenders, investors and other stakeholders, as well as individuals, today announces the acquisition of GWC based in Douglas, which provides advisory and insolvency services across the Isle of Man. The firm's owner, Gordon Wilson, will join FRP as a Partner. The rest of the GWC team comprising eight colleagues will also join FRP.

Global Petroleum 0.075p £1.5m (GBP.L)
The oil and gas upstream exploration Company presently focused on Africa and the Mediterranean’s Executive Chairman, Mr Daniel Page, announces today his resignation as a Director of the Company with immediate effect.

Lexington Gold 4p £14.9m (LEX.L)
The gold exploration and development Company with projects in South Africa and the USA announces that it has signed a drilling contract with Logan Drilling Group to commence its 2024 drilling programme at the Jennings-Pioneer Project on the Carolina Slate Belt, USA. The drilling contract is for a minimum of 430m of diamond drilling with Logan Drilling. The project is expected to start in the week commencing 18 March 2024, with all the requisite approvals already in place.

LoopUp 0.65p £1.3m (LOOP.L)
The cloud telephony provider today provides an in-line trading update. The Group also announces the proposed cancellation of Admission of its ordinary shares to trading on AIM re-registration of the Company as a private limited company and a proposal to undertake a post-Cancellation fundraising as a private company.

MTI Wireless Edge 42p £37m (MWE.L)
The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors announces its audited results for the year ended 31 December 2023. Revenue increased 2% to US$45.6m (FY 2022: US$46.3m). Furthermore, profit before tax increased 12% to US$4.84m (2022: US$4.32m). The net cash position of US$8.1m (FY 2022: US$8.1m) indicates the Company is still in a strong financial position at the end of 2023.

*Roquefort Therapeutics 8p £10,3m (ROQ.L)
The biotech Company focused on developing first in class medicines in the high value and high growth oncology market. The Midkine mRNA Program latest experiments combined the mRNA with a LNP delivery system in a validated in vivo model of liver cancer and demonstrated the safety and efficacy in reducing functional Midkine of the novel mRNA LNP combination. The STAT-6 siRNA Program continued the development of these novel STAT-6 medicines in validated in vitro models of colon cancer with the results demonstrating efficacy of the four new siRNA sequences in reducing STAT-6 expression by 40-50%.

Totally 5.6p £11m (TLY.L)
The provider of frontline healthcare services, corporate fitness and wellbeing services announces it has won a further new insourcing contract for the delivery of Oral and Maxillofacial outpatient and day surgery services for the Saolta University Health Care Group in Ireland. The new contract, valued at £700,000, is for the insourcing of maxillofacial/oral surgery outpatient assessments and day surgery sessions for a 12-month period commencing immediately following mobilisation.

Xeros Technology 2.75p £5.3m (XSG.L)
The Company which develops patented and proven, industry technologies which reduce the environmental impact of how industries make and care for clothes, announces that Alex Tristram has today joined the Board as Finance Director. Alex, who joined Xeros as Group Financial Accounting Manager in January 2018, was appointed Director of Finance (non-board level) and Company Secretary in March 2023.

11 March 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram